Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Managing Pediatric Atopic Dermatitis Nonresponse to Dupilumab and Emerging Therapies

Description

The talk focused on pediatric atopic dermatitis that does not respond adequately to dupilumab, using an 8-year-old child with persistent moderate eczema despite a year of treatment as the main case. The speaker reviewed practical next steps, emphasizing first a careful reassessment of history, adherence, skincare, and whether there was any partial improvement, since that can guide whether to up-dose dupilumab, add topical or other therapies, or consider another diagnosis. A major theme was the importance of looking for concurrent or alternative causes of ongoing eczema, especially allergic or irritant contact dermatitis, and the panel strongly supported patch testing—even while on dupilumab—when disease remains stubborn. The discussion also covered other reasons for dupilumab nonresponse, including nonadherence, occult contact allergy, and possibly endotype differences, and noted that some patients benefit from adding therapies such as methotrexate or using broader immunosuppression if they are true nonresponders. The second half reviewed current and emerging systemic options for children: dupilumab remains the only approved biologic under 12, while IL-13 inhibitors, JAK inhibitors, and newer agents such as OX40 inhibitors are in development. The speaker explained the Th2-driven pathogenesis of atopic dermatitis, how that relates to current and future targeted therapies, and concluded that the field is moving toward biomarker-based endotyping so treatment can eventually be tailored more precisely to individual patients.

View more

Conclusions

In pediatric atopic dermatitis that only partially responds to dupilumab, the next step is often to reassess adherence, optimize topical care, and look for an alternative or concurrent diagnosis rather than immediately abandoning the biologic.
Allergic contact dermatitis is a common and important explanation for apparent dupilumab nonresponse, so patch testing should be strongly considered even while the patient remains on dupilumab.
The degree of prior response matters: partial responders, especially those with other atopic diseases that improve on dupilumab, are more often candidates for dose escalation or add-on therapy, while true nonresponders are more likely to need a switch in treatment.
Chronic urticaria, irritant dermatitis, and environmental triggers such as dust mites and pet dander can masquerade as uncontrolled eczema and should be evaluated in difficult cases.
Dupilumab remains the only FDA-approved systemic biologic option for children under 12, and the available pediatric data support its overall efficacy and safety.
However, a meaningful minority of children remain inadequately controlled, showing that atopic dermatitis is heterogeneous and that one-size-fits-all treatment is often insufficient.
Future management is likely to move toward endotype-based personalization, using biomarkers to better match patients with the therapy most likely to work for their specific inflammatory profile.
Among emerging targeted therapies, IL-13 inhibitors may help some dupilumab failures, but there are no head-to-head data proving superiority or identifying which patients benefit most.
For older children and adolescents, JAK inhibitors such as upadacitinib and abrocitinib appear more effective than dupilumab in head-to-head trials, but their role in younger children is still being studied.
OX40/OX40L inhibitors are promising because they may offer longer-lasting disease modification, but safety concerns remain and the evidence is still evolving.
Overall, the presentation argues that refractory pediatric eczema should prompt a structured reassessment of diagnosis and phenotype before escalating to broader immunosuppression or switching therapies.
The long-term goal is a more precise, biomarker-guided approach that reduces trial-and-error prescribing and improves outcomes for children with atopic dermatitis.

Drucker AM, et al. JAMA Dermatol. 2022.
Guttman-Yassky et al., Lancet, 2025.